Related Experiment Video
Updated: Sep 23, 2025
07:12
Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats
Published on: January 21, 2020
7.8K
CCK2 receptors in chronic pain
Justin E LaVigne1, Sascha R A Alles1
1Dept of Anesthesiology and Critical Care Medicine, University of New Mexico, School of Medicine, Albuquerque, NM 87109, USA.
Neurobiology of Pain (Cambridge, Mass.)
|May 16, 2022
Summary
New strategies targeting the cholecystokinin 2 receptor (CCK2R) offer renewed hope for chronic pain management. This review explores CCK2R
Area of Science:
- Neuroscience
- Pharmacology
- Pain Research
Background:
- The cholecystokinin 2 receptor (CCK2R) system has been a long-standing but largely unsuccessful target for pain relief.
- Recent advancements have reignited interest in CCK2R as a potential therapeutic target for pain management.
Purpose of the Study:
- To review the current understanding of CCK2R in both central and peripheral nervous systems under normal and chronic pain states.
- To examine the interplay between CCK2Rs and opioid systems in pain modulation.
- To summarize recent therapeutic development efforts targeting CCK2R for chronic pain.
Main Methods:
- Literature review of preclinical and clinical studies on CCK2R.
- Analysis of CCK2R expression and function in pain pathways.
- Examination of drug development strategies targeting CCK2R.
Main Results:
- CCK2R plays a role in modulating pain signaling in both the central and peripheral nervous systems.
- CCK2R interacts with opioid receptors, influencing their analgesic effects.
- Emerging therapeutic approaches show promise for CCK2R-based pain treatments.
Conclusions:
- CCK2R remains a viable target for novel chronic pain therapies.
- Further research into CCK2R modulation and its interaction with the opioid system is warranted.
- Developing targeted CCK2R therapies could offer new avenues for effective pain management.
Related Concept Videos
01:25Analgesia and Pain Management
835
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
835
01:44Nociception
29.6K
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain.
29.6K
01:20Pain
656
Pain serves as a critical warning signal that alerts the body to potential or actual harm. When mechanical pressure on the skin is intense, such as from a sharp pinch, the sensation transitions from touch to pain. Similarly, extreme temperatures, like a hot pot handle, convert the sensation of heat into pain. Pain can also result from overstimulation of other senses, such as blinding light, loud noise, or the intense heat from habañero peppers. This ability to sense pain is essential for...
656
01:22Opioid Receptors: Overview
2.1K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
2.1K
01:09GPCRs Regulate Adenylyl Cylase Activity
6.0K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.0K
01:25Cholinergic Receptors: Muscarinic
3.5K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
3.5K